Tendersinfo Gulf

Filter Search

Healthcare and Medical

Location Summary Deadline
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-06
Germany Lamivudine & Abacavir (j05ar02) 2026-06-06
Germany Pharmaceutical Discount Contracts According To § 130a Para. 8 Sgb V Within The Framework Of Open House Procedures 2026-06-06
Germany Open House Discount Contracts 202515 2026-06-06
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Insulin Lispro, Atc A10ab04 And A10ad04 For The Period 01.01.2026 To 31.12.2027 2026-06-06
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V With The Active Ingredient Teriparatide 2026-06-06
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-06
Germany The Tender Involves The Conclusion Of A Non-exclusive Discount Agreement According To § 130a Paragraph 8 Sgb V For The Active Ingredient Lebrikizumab, Atc D11ah10, For The Period From January 1, 2026, To December 31, 2027. The Dak-gesundheit Intends To Co 2026-06-06
Germany Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For The Active Ingredient Guanfacine, Atc N06ba21 For The Period 01.01.2026 To 31.12.2027 (plus Extension Option 1x12 Months) 2026-06-06
Germany Conclusion Of Non-exclusive Discount Agreements According To § 130a Para. 8 Sgb V For The Mentioned Active Ingredients With The Possibility Of Conclusion Within The Framework Of The So-called Open House Procedure. 2026-06-06
Whats app